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Summary
Objective: The repair of osteochondral defects with chondrocytes genetically modiﬁed to express desired growth factors promises great
potential in orthopaedic therapy. Controlled expression of the transgenes is required in many instances. The objective of the present study was
to demonstrate the inducibility of tetracycline-responsive transgene expression in osteochondral defects in the knee joint ﬁlled with genetically
modiﬁed chondrocyte implants.
Methods: An expression plasmid containing the lacZ gene under the control of the minimal CMV promoter fused to the Tet-responsible
element (TRE) as well as the reverse transactivator (rtTA2s-M2) was constructed and used to transfect isolated articular chondrocytes from
New Zealand white rabbits. rtTA2s-M2 binds to the TRE in the presence of tetracycline and leads to the transcription of the transgene. Different
concentrations of DNA and various DNA:lipid ratios were tested to determine best transfection conditions. Transfection efﬁciency and
inducibility were analysed by histochemical analysis and ﬂow-cytometry. To evaluate the system in vivo, collagen-sponges were seeded with
transfected autologous chondrocytes and implanted in osteochondral defects in the knees of NZW-rabbits. Gene expression was induced by
doxycycline and 3 weeks later, LacZ-expression in isolated knee joints was evaluated in histological sections by X-gal staining.
Results: In vitro 13.5% (G1.32) of induced primary chondrocytes were LacZ-positive, while non-induced controls showed a background-
staining in 0.6% (G0.2). In vivo, upon doxycycline treatment, induction of lacZ-gene-expression could be demonstrated in chondrocytes in
3-week-old, well-integrated implants.
Conclusion: For the ﬁrst time, tetracycline-inducible gene expression is demonstrated to work in the treatment of osteochondral defects. This
demonstrates the feasibility for a gene therapy-assisted approach using controlled expression of therapeutic growth factors from transplanted
genetically modiﬁed chondrocytes.
 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Repair
SocietyIntroduction
Articular cartilage defects belong to the very challenging
therapeutic problems1,2. A variety of therapeutic strategies
have the potential to stimulate the formation of new articular
surface, including stimulation of ﬁbrocartilaginous tissue
repair3e5, osteochondral graft transplantation6,7 or autolo-
gous chondrocyte transplantation8. Of importance is that no
synthetic material comes close to the articular cartilage
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Received 3 February 2004; revision accepted 25 May 2004.71level of performance9,10. Although decreased symptoms
are reported in some patients treated with these techniques,
the long-term clinical value is still uncertain and the need for
new treatment methods obvious11,12. Tissue engineering
has become a major ﬁeld in biotechnology during the last
years11. Techniques were developed to isolate and
cultivate cells of a patient to induce cartilage-like tissue.
Type I collagen sponges and other matrices and gels have
previously been shown to be suitable carriers for three-
dimensional culture of chondrocytes13,14.
The use of growth factors in combination with tissue
engineering seems to be reasonable for the therapy of
osteochondral lesions11,15. Some speciﬁc cytokines stimu-
late the cell proliferation and matrix synthesis and can be
used to support healing16e20.
Residual problems are the transient effect and the
difﬁculty of growth factor administration21. A short halﬂife
hampers the direct injection of recombinant cytokines
into the affected joints22. Among different strategies to
overcome this problem gene transfer techniques were1
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primary chondrocytes of various species has been demon-
strated by others26e29. Using constitutive expression
systems, they achieved high transfection rates in vitro and
were able to demonstrate persistent transgene expression
in vivo. These authors imply that constitutive transgene
expression for therapeutic goals ultimately will not be useful
in view of the fact that regulated transgene expression has
several deﬁnite advantages. Cells genetically modiﬁed
ex vivo with growth factors prior to tissue engineering lead
to an enhanced matrix synthesis15,30e33.
However, a gene product involved in chondrocyte-defect
repair is only required during the repair phase. Constitutive,
unregulated expression is not required in most cases and
may lead to an abnormal regulation of cell growth and side-
effects due to chronic over-expression of the cytokine
thereafter34.
For these reasons, a control of timing is preferable over
constitutive gene expression. Among the various inducible
gene expression systems that have been described35 the
tetracycline-inducible system36,37 has the advantage that it
is dependent on a drug (tetracycline or doxycycline) that is
both highly speciﬁc and non-toxic.
Regulation of gene expression by tetracycline is rapid,
reversible and can be modulated38. Tet-controlled expres-
sion has been demonstrated in different cells39, in trans-
genic mice40,41, in the photoreceptor system42, in the
heart43, the brain44,45 and skeletal muscle46,47 but it has
not been previously investigated in chondrocytes or in
osteochondral defects. The recently described doxycycline-
dependent reverse transactivator rtTA2s-M248 was already
successfully used to achieve tightly regulated gene expres-
sion in vitro and in vivo47,49.
The objective of this study was to establish a method for
tetracycline regulated gene expression in chondrocytes
transplanted into osteochondral defects of living animals.
Using chondrocytes transfected with a tetracycline-induc-
ible expression plasmid, we demonstrate that transgene
expression in these cells can be induced in vivo after
implantation.
Materials and methods
ANIMALS
The study has been approved by the appropriate
institutional review board. Animals were kept according to
FELASA-guidelines. Female CD1 nu/nu mice (6e8 weeks
old) and 6 weeks old New Zealand white rabbits were
obtained from Charles River (Sulzfeld, Germany) and kept
under conventional housing conditions. Quarantine lasted
7 days. The animals were housed with appropriate bedding,
provided with free access to drinking water and food. Mice
were maintained in IVC-cages, rabbits in V2A-cages under
conditions of controlled temperature and light.
CHEMICALS
Reagents were obtained from Biochrom (DMEM, Pen/
Strep, Glutamin, FBS, PBS, Trypsin), Roche (Collagenase
A, FuGENE 6), SigmaeAldrich (X-Gal, Doxycycline),
Invitrogen (LipofectAmine), and Resorba Clinicare
(Collagen Sponge).CELL CULTURE/TISSUE ENGINEERING
NIH-3T3-cells were obtained from ATCC (CCL-1658),
293T cells50 were obtained from R. Willemsen (Daniel den
Hoed Cancer Center, Rotterdam, The Netherlands).
Articular cartilage was obtained from knee joints of New
Zealand white rabbits under general anesthesia. At the time
of biopsy, 6 weeks old New Zealand white rabbits (average
weight 1.8 kg) were used. Sterile harvested cartilage was
washed twice in PBS, cut in 1 mm3 pieces, minced and
digested on a shaker with 0.25% trypsin (30 min) and
50 mg/20 ml (0.21 U/mg) Collagenase A (4e6 h). The
resulting solutions were centrifuged at 900 rpm for 4 min.
Cell pellets were resuspended in medium. The isolated
chondrocytes were seeded in 25 cm2 ﬂasks, grown to
a density of 80%, then seeded in 75 cm2 ﬂasks and splitted
at a ratio of 1:3 every 5th day.
Cell viability and numbers were determined by trypan
blue staining. Ten to 14 days following biopsy, the adherent
cells were released from the dishes by a 3 min-exposure to
0.25% trypsin. Chondrocytes (6! 105) were seeded on
a 4 mm3 piece of a commercially available type I collagen
sponge (Resorba, Nu¨rnberg, Germany) by injection with
a needle (27G). After seeding, the medium was changed
every 2nd day.
Cells were grown in Dulbecco’s modiﬁed Eagles medium
containing 10% fetal bovine serum, 1% Pen/Strep and 1%
glutamine and maintained at 37(C, 5% CO2. After 14 days
in culture, the collagen sponges were dissolved with
Collagenase A, cells isolated and cell viability and number
were determined by trypan blue staining.
PLASMIDS
All tet-regulatory elements were cloned into one construct
to circumvent the need for double transfection of each cell.
The plasmid used for tetracycline-controlled gene expres-
sion is based on a modiﬁed version of the retroviral
construct pN2A51, comprising a neomycin resistance gene
under the control of the 5#LTR promoter and a multiple
cloning site (MCS) located in the U3 Region of the 3#LTR.
pN2A was modiﬁed by insertion of a poly(A) signal in
antisense orientation in the MCS, yielding the vector
pN2AP.
In the ﬁrst step pTRE2 (Clontech, Palo Alto, CA, USA)
was digested with XhoI and EcoRV and treated with Klenow
enzyme. The 537 bp fragment containing the Tet-responsi-
ble element fused to the minimal CMV promoter followed by
an MCS was isolated and cloned in antisense orientation
into the SnaBI site of the linearized vector pN2AP. The
resulting plasmid was designated pN2ATRE.
In the second step rtTA2s-M2 under the control of the
hCMV promoter was obtained by XhoI and BamHI digestion
of the plasmid pUHrt 61-148 (kindly provided by H. Bujard,
Heidelberg). After treatment with Klenow enzyme the 1.5 kb
fragment was cloned into the SfuI digested pN2ATRE to
obtain pN2ATetOn.
The lacZ gene was cloned into the Klenow enzyme
treated NotI site of pN2ATetOn, yielding pN2ATetOnLacZ.
TRANSFECTION OF CELLS AND INDUCTION OF
GENE EXPRESSION
NIH-3T3 cells were stably transfected using Lipofect-
Amine and selection with G 418 (1 mg/ml). Cell clones
were picked and screened for tetracycline-dependent
transgene expression.
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Then 2! 105 cells were trypsinized and transferred to
a 60 mm plate. To determine best transfection conditions,
lipid/DNA ratios and the DNA dose were varied according to
the suggestions of the manufacturer (2e6 mg DNA per well,
FuGENE:DNAZ 2 or 3 v/w). We next investigated the best
time course of LacZ-induction. Doxycycline at a dosage of
1 mg/ml was added and cells were incubated for 12, 24 and
36 h before ﬁxation and staining. The efﬁciency of gene
transfer was measured by histochemical examination of
b-galactosidase activity in the cells using the chromogenic
substrate X-gal and also by ﬂow-cytometry (FACS) with the
ﬂuorescein-containing LacZ-substrate ﬂuorescein-b-D-gal-
actopyranosid (FDG)52 with an adaptation according to
Kru¨ger et al.53.
INJECTION OF NIH-3T3-CELLS AND IN VIVO INDUCTION OF
b-GALACTOSIDASE EXPRESSION
Cell suspensions were injected subcutaneously in 8 nude
mice in both ﬂanks (1.5e9! 106 cells in 200 ml PBS). Four
weeks later, after the tumors were grown, lacZ-gene-
expression was induced in 6 mice by addition of doxycy-
cline to the animals’ drinking water (1 mg/ml). Drinking
water was changed daily as doxycycline is light sensitive
and labile in solution. Two mice received water without the
antibiotic as control.
PREPARATION OF TUMOR EXTRACTS AND HISTOLOGICAL
EVALUATION
Mice were sacriﬁced after sedation by an overdose of
pentobarbital 24, 48 resp. 72 h after induction and the
tumors excised. One half of each tumor was cut in 3 mm3
pieces, ﬁxated immediately in 0.5% glutaraldehyde for 1 h
at room temperature and stained with X-gal staining
solution. For histologic staining of LacZ, the other half of
the tumors were cut into slices with a thickness of 7 mm in
a cryotome. The slices were ﬁxed in glutaraldehyde and
incubated for 6 h in X-gal staining solution. The tissue slices
were counterstained by hematoxylineeosin.
GENERATION OF OSTEOCHONDRAL LESIONS AND IMPLANTATION
OF CHONDROCYTE-SEEDED COLLAGEN SPONGES
By the time of implantation of the cell-seeded sponges,
animals had reached an average weight of 3 kg. The rabbits
were anesthetized by i.m. injection of 0.25 mg/kg medeto-
midine and 17 mg/kg S-ketamine. After intubation 30 mg/kg
metamizole i.v. and 4 mg/kg carprofen s.c. were adminis-
tered. Using sterile technique a medial parapatellar
arthrotomy was performed and the patella was laterally
displaced. In the ﬁrst surgery a small biopsy (1! 1 mm)
was taken from the trochlear groove. In the second surgery
a steel drill (3.6 mm in diameter) with a stop-device was
used to create a full-thickness defect (3 mm deep) in the
articular cartilage of the trochlear groove of the contralateral
knee. The defects were cleaned and rinsed with sterile
saline. The chondrocyte-collagen implants were press-ﬁtted
into the drill-holes. In one animal of the doxycycline induced
group two defects were generated to have an internal
control: non-transfected cells were implanted into a proximal
and pN2TetOnLacZ-transfected cells into a distal defect, as
shown in Fig. 4B. The sponges were held in place within the
defects by repositioning of the patella within the trochlear
groove. After extubation, all rabbits were returned to theircages and were allowed free cage activity. Postoperative
analgesia consisted of 0.03 mg/kg buprenorphin on the
surgery day and 4 mg/kg carprofen for 3 days.
In 10 rabbits gene expression was induced 14 days after
surgery for 7 consecutive days by daily subcutaneous
injections of 1 mg/kg doxycycline per day. This antibiotic is
well distributed into the synovial ﬂuid, the amount measured
in the joint approaches that in plasma54. The control group
of 4 rabbits did not receive doxycycline.
PREPARATION OF FEMORAL CONDYLES AND HISTOLOGICAL
EVALUATION
Rabbits were sacriﬁced after anesthesia with propofol by
fast injection of 5 ml pentobarbital 3 weeks after implanta-
tion. The knee joints were harvested, assessed macro-
scopically and photographed after ﬁxation (2%
formaldehyde, 0.2% glutaraldehyde in PBS) and color-
development after X-gal staining. The condyles were
decalciﬁed in EDTA (10%) for 3 weeks and embedded in
parafﬁn. Serial sections were cut transversely, from the
proximal aspect to the distal aspect of the trochlear groove.
Sections (6 mm) from the center of each defect were
counterstained with hematoxylineeosin, eosin and nuclear
fast red for histological evaluation.
STATISTICAL ANALYSIS
Data are expressed as meanG standard deviation (SD)
of separate experiments. Each test condition was per-
formed in quadruplicate for the determination of transfection
conditions and time-course experiments. Student’s t-test
was used to determine the signiﬁcance of differences
between groups. P values less than 0.05 were considered
signiﬁcant.
Results
DOXYCYCLINE-INDUCIBILITY OF LACZ EXPRESSION OF
PN2TETONLACZ IN CELL LINES IN VIVO
To verify that LacZ expression of our plasmid construct
was doxycycline-inducible, we injected a tumorgenic
subline of NIH-3T3-ﬁbroblasts, stably transfected with
N2TetOnLacZ, into 8 nu/nu mice subcutaneously in both
ﬂanks. Four weeks after injection 14 tumors grew to an
average size of 341 mm3. Forty-eight hours after induction
of gene expression with doxycycline, mice were sacriﬁced
and tumors analysed histologically after X-gal staining to
evaluate LacZ-activity. Sections of the tumors showed
a slight blue background-staining in the non-induced group,
possibly due to basal activity of the TRE promoter in the
absence of doxycycline [Fig. 1(A)] and an intensive LacZ-
staining in the induced group [Fig. 1(B)]. Tumors were not
fully stained, because the staining solution did not penetrate
the specimen within 6 h. Histologic evaluation demon-
strated the slight stained cells in the control group and the
intensive blue cells in the induced group (data not shown).
TRANSFECTION OF CHONDROCYTES AND INDUCTION OF
GENE EXPRESSION
To test, whether these results could be reproduced with
articular chondrocytes, we transfected these cells with
N2TetOnLacZ. The efﬁciency of gene transfer was mea-
sured by histochemical examination of b-galactosidase
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and also by ﬂow-cytometry (FACS). Transfection efﬁciency
varied with the total DNA dose, but not with the lipid/DNA
ratio. Maximal transfection efﬁciency (13.5G 1.32%) was
seen with 12 ml FuGENE and 4 mg DNA (ratio 3:1) in
a 60 mm plate in induced cells (Fig. 2), although there was
no signiﬁcant difference compared to lipid/DNA ratio of 2:1
(13.2G 0.74%). Non-induced controls demonstrated LacZ-
staining in 0.55G 0.17% (lipid/DNA ratio 2:1) and
0.6G 0.2% (lipid/DNA ratio 3:1) of cells (Fig. 2). LacZ
staining was much more intensive in the induced cells
compared to the non-induced controls [Fig. 3(A and B)].
Due to leakiness of transgene expression caused by the
basal activity of the TRE promoter in the absence of
docycycline, cells expressed background LacZ activity. No
further increase in efﬁciency was obtained with lower or
higher DNA concentrations. Maximal induction was gener-
ally achieved after 24 h treatment with doxycycline.
Fig. 2. LacZ-expression in N2TetOnLacZ-transfected rabbit articu-
lar chondrocytes. Chondrocytes were transfected with FuGENE 6/
DNA ratios of 2:1 and 3:1. Forty-eight hours after transfection cells
were induced by doxycycline (1 mg/ml) and incubated for additional
24 h. Efﬁciency of gene transfer was measured by ﬂow-cytometry
(FACS). Data are expressed as mean transfection efﬁciency
(n ¼ 3) G standard deviation.
Fig. 1. Sections of NIH-3T3 cell-induced tumors in nude mice. A
stably N2TetOnLacZ-transfected NIH-3T3-clone was used. Tumors
were excised, cut and stained with X-gal for 6 h. (A) Non-induced
controls demonstrate a background staining; (B) administration of
doxycycline in drinking water induced LacZ-expression in vivo.
Tumors were not fully stained, because the staining solution did not
penetrate the specimen within 6 h.CHONDROCYTE-SEEDED COLLAGEN SPONGES IN VITRO
We next determined the growth and viability of trans-
fected cells seeded onto collagen sponges. Seeding the
chondrocytes on collagen sponges resulted in growth of
cells only on the surface of the scaffold. Only after injection
with a ﬁne needle into the center of the sponges, cells were
distributed throughout the entire matrix (data not shown).
After 14 days in culture the mean number of cells recovered
from the collagen sponges after treatment with Collagenase
A was 5.2! 105 (G0.6) or 86% of the number of cells
originally injected into the sponge prior to incubation. Cell
viability amounted to 94% (G2.3%) of the cells recovered
from the sponge. In tissue culture in vitro, living cells could
be maintained in collagen sponges up to 6 weeks.
Because cells were harvested from superﬁcial layers of
hyaline cartilage in the trochlear groove of the patella, we
considered them to be chondrocytes.
REGULATION OF LACZ-EXPRESSION IN OSTEOCHONDRAL
DEFECTS IN VIVO
Three weeks after implantation of the chondrocyte-
collagen sponges, animals were sacriﬁced and femoral
Fig. 3. Light microscopy of N2TetOnLacZ-transfected chondrocytes
in cell culture. (A) Transfected chondrocytes without doxycycline-
induction. Cells express a slight blue LacZ-activity likely due to
leakiness referring to basal activity of the TRE promotor in the
absence of doxycycline; (B) transfected chondrocytes with doxy-
cycline-induction: LacZ-expression was detected 24 h after in-
duction with 1 mg/ml doxycycline in 9.6% of the cells. Original
magniﬁcation !100.
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regenerative tissue appeared smooth and resembled the
surrounding articular cartilage [Fig. 4(A)]. Some areas
showed slight indentation. Small ﬁssures could be de-
termined in the central parts of most of the transplants. No
chondral reactions occurred on the opposite patella. In
treated joints a mild synovitis could be seen.
To exclude unspeciﬁc X-gal staining, one animal with two
defects in the same joint was evaluated: in the proximal
defect, we implanted non-transfected cells on the collagen
sponge, in the distal defect N2TetOnLacZ-transfected cell-
bearing sponges were used. After treatment with X-gal, only
the distal defect exhibited macroscopically a blue staining,
whereas the proximal defect remained unstained [Fig. 4(B)].
Notably, both the induced and the uninduced cells were
stained to a lesser degree. A three-dimensional view ofa transverse cut section through the condyle revealed the
depth of the stained cells in the implant [Fig. 4(C)].
Histologically, the implants appeared well integrated into
the cartilage and bone [Fig. 5(A)]. Chondrocytes showed
a columnar appearance and proliferation in lacunae even in
the center of the osteochondral defect [Fig. 5(B)]. Collagen
ﬁbers of the cell-bearing sponge as well as newly
synthesised collagen could be demonstrated. Non-induced
controls showed several lightly stained cells across the
entire section of the condyle but did not show LacZ-activity
over the background (data not shown). In the doxycycline-
treated group, transfected chondrocytes in the collagen
matrices were strongly stained, demonstrating an efﬁcient
induction of LacZ-expression [Fig. 6(AeC)]. Counterstain-
ing with eosin and nuclear fast red was used to highlight
b-galactosidase positive blue cells (data not shown).Fig. 4. Femoral condyles 3 weeks after implantation of chondrocyte-seeded collagen sponges. (A) Non-induced control specimens did not
demonstrate X-gal staining macroscopically; (B) as an internal control and to detect possible unspeciﬁc X-gal staining two defects were
generated in one animal: non-transfected cells were implanted into the proximal and N2TetOnLacZ-transfected cells into the distal defect.
X-gal staining was detected in the defect with the transfected cells after treatment with doxycycline only; (C) transversely cut section through
a femoral condyle of the induced group demonstrating the depth and the cumulative effect of X-gal stained cells in the defect; bZ bone,
cZ cartilage, iZ implant, mZ margins of the defect.
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induced group showed inﬁltrating lymphocytes on the
margins of the defect, possibly an immunologic response
to the b-galactosidase-protein. Immunohistochemistry with
CD-3 and CD-20 was done to differentiate between T- and
B-lymphocytes. Both stainings were positive, demonstrating
an immunologic reaction was taking place. These lympho-
cyte inﬁltrations were not seen in the non-induced group
(data not shown).
A difference between both groups regarding regeneration
of hyaline cartilage was not expected and could obviously
not be determined.
Discussion
The goal of our study was to develop a system of
controllable transgene expression in articular chondrocytes
to be used in the therapy of osteochondral defects. To
achieve our aim, we chose the tetracycline-inducible gene
expression system.
After in vitro characterization of transfected chondrocytes,
inducible gene regulation was assessed in vivo. To
transplant the manipulated cells, we seeded them onto
Fig. 5. Histologic analysis of an osteochondral defect 3 weeks after
implantation, demonstrating repair of the lesion by the collagen-cell-
sponge; b Z bone, c Z chondrocytes and collagen ﬁbers,
mZ margins of the defect. Section from a control animal that did
not receive doxycycline, the uninduced transgene cells did not
reveal LacZ-staining. X-gal staining and hematoxylin/eosin, original
magniﬁcation A: !40, B: !100, detail in higher magniﬁcation.collagen-sponges. Previous studies have used a periosteal
cap, as well as collagen I sponges55 to retain transplanted
chondrocytes in cartilage defects. We choose to trans-
plant our genetic manipulated chondrocytes on collagen I
sponges, because cells grown on these matrices are phe-
notypically stable, metabolically active and express extra-
cellular proteins characteristic for articular cartilage56. With
our technique injecting the cells into the collagen sponge
Fig. 6. Inducible LacZ-expression in chondrocytes after doxycycline
treatment; bZ bone, xZ induced LacZ-expressing cells, mZ
margins of the defect. Section from an animal given doxycycline
1 mg/kg subcutaneously for 1 week. Induced transgene cells
demonstrate intensive LacZ-staining. X-gal staining and hematox-
ylin/eosin, original magniﬁcation A: !40, B: !100, C: !200.
717Osteoarthritis and Cartilage Vol. 12, No. 9with a ﬁne needle, we achieved a cell growth even in the
deeper areas of the scaffold whereas other groups ob-
served cell growth only on the surface55.
N2TetOnLacZ-transfected autologous chondrocytes,
seeded on type I collagen sponges and implanted in
artiﬁcial osteochondral defects in the trochlea femoris of
NZW-rabbits, expressed the marker gene LacZ and
became LacZ-positive in animals which obtained doxycy-
cline to induce expression of the transgene. In contrast,
transduced cells of animals in the non-induced group
showed only slight transgene expression, which is consis-
tent with our observation in cell culture. In a recent study,
Lamartina et al.47 reported tight control of transgene
expression in vitro and in vivo in a nonviral vector system
by the novel reverse transactivator rtTA2s-M2 and another
mutant rtTA2s-S2. This is also reported by Koponen et al.49
who used rtTA2s-M2 in a lentiviral vector system. Obtaining
high levels of induction, both groups observed very low
basal activity in the non-induced state of their systems. This
is consistent with our data which show slight basal
expression of our transgene in the non-induced state both
in vitro and in vivo.
How many of our transfected cells survived in vivo could
not be determined but the number was substantial as
shown in Fig. 6.
Of interest was the observation of mononuclear cell
inﬁltration in the adjacent cell layers in the transgene
expressing knee joints, documenting the immunogenicity of
the transfected cells, probably due to the expression of the
reporter gene57,58. This is not envisaged to represent
a problem if the transgene is one coding for an endogenous
growth factor.
Thus, our experiments document the feasibility of using
a nonviral tet-inducible system to regulate transgene
expression in vivo after implantation of genetically modiﬁed
chondrocytes. In future, this approach might be used for
a controlled delivery of therapeutic genes such as Bone
Morphogenetic Proteins (BMP), Transforming Growth Fac-
tor-b (TGF-b), or Insulin-like Growth Factor-1 (IGF-1) in
cartilage defects to study the mechanism of the growth
factor cascade in the articular healing process.
The successful clinical application of nonviral vectors will
rely on a better understanding of the barriers to gene
transfer and on the development of vectors that can
overcome such barriers.
These results may serve as a ﬁrst step of combining
inducible gene expression in chondrocytes with tissue
engineering. More information further deﬁning safety ques-
tions of gene delivery into primary cells is needed before this
approach enters the clinic. Certainly a system that allows
controlled gene expression is a step in the right direction.
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